HEAR FROM PEERS
Peer-to-peer learning hub
Play Video
Improving ILD Diagnosis and Predicting Clinical Progression with the Envisia Genomic Classifier
Speakers discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD. New data is presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic ILD.
Case Studies & Presentations
Envisia resource library
Watch case studies and testimonials from physicians or on-demand videos about Envisia and its clinical utility.
Case studies & testimonials
On-demand presentations
- POSTED ON
- May, 2021
Utility of Envisia Genomic Classifier in Multi Disciplinary ILD Management at ATS 2021
Panelists discuss the challenges in making an early accurate diagnosis in patients with diverse Interstitial Lung Diseases (ILD), review the latest published clinical validation and utility data for the Envisia Genomic Classifier, and discuss the role of the Envisia classifier in the diagnosis and prognosis of ILD patients.
- POSTED ON
- Mar 26, 2021
Envisia Physician Testimonial
Hear from Dr. Nina Maouelainin how she integrated Envisia Genomic Classifier into her clinical practice and the test’s impact on patient management.
Detects genomic UIP pattern to improve ILD diagnostic confidence
Usual interstitial pneumonia (UIP) is a critical factor in differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs). The Envisia classifier improves ILD diagnostic and prognostic confidence, and can identify twice as many UIP patients than radiology alone when combined with HRCT.